Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase NA 5Phase 1/2 4Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 573Sarcoma 179Gastrointestinal 8Thoracic 7Gynecologic 5Lymphoid 4Head & Neck 4Genitourinary 4Dermatologic 4Classical hematology 4Breast 4Other solid neoplasm 3Plasma cell 2Endocrine 2Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 985Leukemia 733Leukemia, Lymphocytic, Chronic, B-Cell 665Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Myelodysplastic Syndromes 502Lymphoma 340Leukemia, Myelogenous, Chronic, BCR-ABL Positive 308Lymphoma, Non-Hodgkin 294Hematologic Neoplasms 257Lymphoma, Follicular 223Multiple Myeloma 213Burkitt Lymphoma 209Hodgkin Disease 198Lymphoma, Large B-Cell, Diffuse 194Lymphoma, Mantle-Cell 193Lymphoma, B-Cell, Marginal Zone 189Leukemia, Myelomonocytic, Chronic 181Leukemia, Myeloid, Chronic-Phase 171Recurrence 167Myeloproliferative Disorders 165Congenital Abnormalities 140Lymphoma, Large-Cell, Immunoblastic 132Leukemia, Myeloid, Accelerated Phase 118Blast Crisis 115Anemia, Refractory, with Excess of Blasts 114Waldenstrom Macroglobulinemia 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Primary Myelofibrosis 94Graft vs Host Disease 88Neoplasms, Plasma Cell 84

Interventions

ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × Other hematologic neoplasm × Clear all
NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡